For example, some studies have shown that TP53 mutations may predict response to HMAs, whereas others did not confirm that finding.13,17 In a small study of 84 patients with acute myeloid leukemia (AML) and MDS treated with a 10-day DAC course, a small subset of patients with TP53 mutations had a higher response rate to DAC compared with TP53 wild-type patients. The gene discussed is TP53; the disease is myelodysplastic syndrome.